HYCAMTIN

LOE Approaching

topotecan hydrochloride

NDAINJECTIONINJECTABLEPriority Review
Approved
May 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4

Mechanism of Action

single-strand breaks. Topotecan binds to the topoisomerase I‑DNA complex and prevents re-ligation of these single-strand breaks. The cytotoxicity of topotecan is thought to be due to double-strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex…

Clinical Trials (4)

NCT02357810Phase 2Completed

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

Started Mar 2015
178 enrolled
Adult LiposarcomaMetastatic LiposarcomaMetastatic Osteosarcoma+4 more
NCT01037023N/ACompleted

Regulatory Hycamtin(Oral) PMS

Started Oct 2010
92 enrolled
Lung Cancer, Small Cell
NCT00390806Phase 3Completed

Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer

Started Dec 2006
472 enrolled
Lung Cancer, Non-Small Cell
NCT00316186Phase 2Completed

First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin

Started Jun 2005
33 enrolled
Lung Cancer, Small Cell